Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Certificate Accreditation Program (CAP) has released a one-year transition plan for certificate issuers to undergo full migration from ANSI/ASTM E2659-18, Standard Practice for Certificate Programs, ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

As of 14 February at 2:45:35 pm GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

AnaptysBio, Inc. (NASDAQ:ANAB) shareholders should be happy to see the share price up 13% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In fact ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.